Anna Linnér1, Jessica Darenberg2, Jan Sjölin3, Birgitta Henriques-Normark4, Anna Norrby-Teglund1. 1. Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm. 2. Public Health Agency of Sweden, Solna. 3. Department of Infectious Diseases, Uppsala University. 4. Public Health Agency of Sweden, Solna Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm Karolinska University Hospital, Solna, Sweden.
Abstract
BACKGROUND: Streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis are the 2 most severe invasive manifestations caused by group A Streptococcus (GAS). Intravenous immunoglobulin (IVIG) therapy has been suggested as adjunctive treatment with a beneficial effect on mortality. However the clinical evidence is limited. Here we aim to further document the clinical efficacy of administered IVIG therapy in a comparative observational study of well-defined patients with STSS. METHODS: The effect of IVIG was evaluated in patients with STSS prospectively identified in a nationwide Swedish surveillance study conducted between April 2002 and December 2004. Detailed data on symptoms, severity of disease, treatment, and outcome were obtained from 67 patients. Crude and adjusted analyses with logistic regression were performed. RESULTS: Twenty-three patients received IVIG therapy compared with 44 who did not. No significant difference in comorbidities, severity of disease, organ failures, or sex was seen, but the IVIG group was slightly younger and had a higher degree of necrotizing fasciitis (56% vs 14%). The primary endpoint was 28-day survival. Adjusted analysis revealed that factors influencing survival in STSS were Simplified Acute Physiology Score II (odds ratio [OR], 1.1; P = .007), clindamycin (OR, 8.6; P = .007), and IVIG (OR, 5.6; P = .030). CONCLUSIONS: This comparative observational study of prospectively identified STSS patients demonstrates that both IVIG and clindamycin therapy contribute to a significantly improved survival in STSS.
BACKGROUND:Streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis are the 2 most severe invasive manifestations caused by group A Streptococcus (GAS). Intravenous immunoglobulin (IVIG) therapy has been suggested as adjunctive treatment with a beneficial effect on mortality. However the clinical evidence is limited. Here we aim to further document the clinical efficacy of administered IVIG therapy in a comparative observational study of well-defined patients with STSS. METHODS: The effect of IVIG was evaluated in patients with STSS prospectively identified in a nationwide Swedish surveillance study conducted between April 2002 and December 2004. Detailed data on symptoms, severity of disease, treatment, and outcome were obtained from 67 patients. Crude and adjusted analyses with logistic regression were performed. RESULTS: Twenty-three patients received IVIG therapy compared with 44 who did not. No significant difference in comorbidities, severity of disease, organ failures, or sex was seen, but the IVIG group was slightly younger and had a higher degree of necrotizing fasciitis (56% vs 14%). The primary endpoint was 28-day survival. Adjusted analysis revealed that factors influencing survival in STSS were Simplified Acute Physiology Score II (odds ratio [OR], 1.1; P = .007), clindamycin (OR, 8.6; P = .007), and IVIG (OR, 5.6; P = .030). CONCLUSIONS: This comparative observational study of prospectively identified STSS patients demonstrates that both IVIG and clindamycin therapy contribute to a significantly improved survival in STSS.
Authors: Martin B Madsen; Peter B Hjortrup; Marco B Hansen; Theis Lange; Anna Norrby-Teglund; Ole Hyldegaard; Anders Perner Journal: Intensive Care Med Date: 2017-04-18 Impact factor: 17.440
Authors: Christine S Cocanour; Phillip Chang; Jared M Huston; Charles A Adams; Jose J Diaz; Charles B Wessel; Bonnie A Falcione; Graciela M Bauza; Raquel A Forsythe; Matthew R Rosengart Journal: Surg Infect (Larchmt) Date: 2017-04-04 Impact factor: 2.150
Authors: Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan Journal: Virulence Date: 2016-12-07 Impact factor: 5.882
Authors: Peter A Szabo; Ankur Goswami; Delfina M Mazzuca; Kyoungok Kim; David B O'Gorman; David A Hess; Ian D Welch; Howard A Young; Bhagirath Singh; John K McCormick; S M Mansour Haeryfar Journal: J Immunol Date: 2017-02-20 Impact factor: 5.422